Proactive Investors - Run By Investors For Investors

Dynavax shares skyrocket after its Hepatitis B drug gets US FDA advisory committee approval

Dynavax said should the vaccine be given the green light, it will seek a recommendation from the CDC's immunization practices advisory committee and plans a commercial launch of the vaccine in early 2018 "on its own or through a commercial partner."
injection
Dynavax shares have surged 88.11% to $17.40 in premarket trade.

Dynavax Technologies Corp. (NYSE:DVAX) shares jumped 88% in premarket trade Monday after a US Food and Drug Administration (FDA) advisory committee said the safety data for its Hepatitis B vaccination supported its approval.

The advisory committee voted 12 to 1 on the safety data, with three members abstaining.

A previous advisory committee had voted 13 to 1 in favor of the vaccine's ability to promote an immune response.

On Monday, Dynavax was upgraded to overweight at J.P. Morgan with a US$27 price target and upgraded to outperform at RBC Capital Markets with a US$26 price target.

Although there are already Hepatitis B vaccines in the market, they require three doses administered over six months, while Dynavax's HEPLISAV-B vaccine only requires two doses over a month period, the company said.

An FDA decision on the approval of the vaccine is expected by August 10.

Dynavax said should the vaccine be given the green light, it will seek a recommendation from the CDC's immunization practices advisory committee.

The company plans a commercial launch of the vaccine in early 2018 "on its own or through a commercial partner."

Dynavax shares have surged 88.11% to $17.40 in premarket trade and then later gained 76% to $16.37 each.

View full DVAX profile View Profile

Dynavax Technologies Timeline

Related Articles

researcher
May 01 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
An instrument made by Pressure BioSciences
June 26 2019
The company’s high-pressure technologies can help drug makers produce protein-based therapeutics, a market expected to touch $240 billion by 2023
Social media use
April 19 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use